The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis

Magnetic resonance imaging (MRI) has been a valuable tool to understand the pathophysiology and natural history of multiple sclerosis (MS), and increasing attention is focusing on the use of MRI findings as outcome measures in treatment trials in MS. The recently completed trial of interferon‐β‐1b (IFN‐β1b) demonstrated a decrease in accumulation of diseased tissue on T2‐weighted images and a reduction in new lsions on T2‐weighted images. To examine the effect of IFN‐β1b on blood‐brain barrier (BBB) breakdown, and to provide additional insights into the usefulness of MRI in the evolution of effectiveness of experimental treatments in MS, we used the contrast‐enhanced lesion frequency of 7‐month baseline MRIs compared with the enhanced lesion frequency for 6‐month treatment period MRIs in 14 relapsing‐remitting (RR) MS patients. Longer baselines were also available for analysis in a subset of 8 patients, as these patients had been followed by monthly MRI in a natural history study for up to 4 years prior to the current study. A significant reduction in the total or new enhancing lesion frequency was detected in the patients analyzed as a whole, and 13 of 14 of the patients demonstrated a reduction in enhancing lesion frequency on treatment over the 6 months studied. These findings suggest that IFN‐β has a mechanism of action that at least temporarily inhibits the opening of the BBB in RRMS patients. This trial also illustrates the usefulness of a baseline versus treatment trial design to evaluate the effect of drug therapy in MS.

[1]  H. McFarland,et al.  Outcomes assessment in multiple sclerosis clinical trials: a critical analysis , 1995, Multiple sclerosis.

[2]  B Efron,et al.  Statistical Data Analysis in the Computer Age , 1991, Science.

[3]  J A Frank,et al.  Serial contrast‐enhanced magnetic resonance imaging in patients with early relapsing–remitting multiple sclerosis: Implications for treatment trials , 1994, Annals of neurology.

[4]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[5]  K. Heilman,et al.  Visual grasp in corticobasal degeneration , 1994, Annals of neurology.

[6]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[7]  D. Miller,et al.  Magnetic resonance in monitoring the treatment of multiple sclerosis , 1994, Annals of neurology.

[8]  C. Raine.  The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesion , 1994, Annals of neurology.

[9]  J A Frank,et al.  Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. , 1994, Statistics in medicine.

[10]  H. McFarland,et al.  Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.

[11]  C. Raine,et al.  Multiple sclerosis: immune system molecule expression in the central nervous system. , 1994, Journal of neuropathology and experimental neurology.

[12]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[13]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[14]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[15]  D. Miller,et al.  Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon‐β , 1994, Annals of neurology.

[16]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[17]  R. Rudick,et al.  The use of brain magnetic resonance imaging in multiple sclerosis. , 1994, Archives of neurology.

[18]  W. I. McDonald,et al.  Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.

[19]  A. Cross,et al.  Hypothesis: Antigen-specific T cells prime central nervous system endothelium for recruitment of nonspecific inflammatory cells to effect autoimmune demyelination , 1991, Journal of Neuroimmunology.

[20]  D. Li,et al.  Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis , 1994, Annals of neurology.

[21]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs , 1994, Journal of the Neurological Sciences.